Suppr超能文献

一名患有新型X连锁凋亡抑制蛋白(XIAP)变异的男孩,其爱泼斯坦-巴尔病毒相关噬血细胞性淋巴组织细胞增生症并发冠状动脉扩张和急性肾损伤:病例报告

Epstein-Barr virus-related hemophagocytic lymphohistiocytosis complicated with coronary artery dilation and acute renal injury in a boy with a novel X-linked inhibitor of apoptosis protein (XIAP) variant: a case report.

作者信息

Chen Ru-Yue, Li Xiao-Zhong, Lin Qiang, Zhu Yun, Shen Yun-Yan, Xu Qin-Ying, Zhu Xue-Ming, Bai Zhen-Jiang, Li Ying

机构信息

Department of Nephrology and Immunology, Children's Hospital of Soochow University, Suzhou, Jiangsu, China.

Department of Pathology, Children's Hospital of Soochow University, Suzhou, Jiangsu, China.

出版信息

BMC Pediatr. 2020 Oct 2;20(1):456. doi: 10.1186/s12887-020-02359-4.

Abstract

BACKGROUND

X-linked lymphoproliferative disease (XLP) is a rare inherited X-linked primary immunodeficiency diseases (PID). One such disease, X-linked inhibitor of apoptosis protein (XIAP) deficiency, is characterized by Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH). However, EBV-HLH with coronary artery dilation and acute renal injury (AKI) in children is unusual.

CASE PRESENTATION

We report the case of a young boy aged 17 months with a novel XIAP variant. He was initially diagnosed with EBV-HLH based on the HLH-2004 diagnostic criteria and the condition was accompanied by coronary artery dilation and acute renal injury. The comprehensive genetic analysis of peripheral blood-derived DNA revealed a hemizygous variant of the XIAP gene [c.116G > C(p.G39A)], which was inherited from his mother (heterozygous condition). After combined treatment with rituximab, intravenous immunoglobulin, corticosteroids, antiviral drugs, and mycophenolate mofetil (MMF) in addition to supportive therapy, his clinical manifestations and laboratory indexes were improved. The patient achieved complete remission with MMF treatment in the 8-month follow-up.

CONCLUSIONS

We report the [c.116G > C(p.G39A)] variant in the XIAP gene for the first time in a case of XLP-2 associated with EBV-HLH. For male patients with severe EBV-HLH, the possibility of XLP should be considered and molecular genetic testing should be used early in auxiliary diagnosis. Reports of EBV-HLH with coronary artery dilation and AKI in children are rare. In the patients with EBV-HLH, color Doppler echocardiography and urine tests should be monitored regularly. If necessary, renal biopsy can be performed to clarify the pathology. Treatment with rituximab, immunosuppressors and supportive therapy achieved a good effect, but long-term follow-up is required.

摘要

背景

X连锁淋巴增殖性疾病(XLP)是一种罕见的遗传性X连锁原发性免疫缺陷病(PID)。其中一种疾病,X连锁凋亡抑制蛋白(XIAP)缺乏症,其特征为与爱泼斯坦-巴尔病毒相关的噬血细胞性淋巴组织细胞增生症(EBV-HLH)。然而,儿童EBV-HLH合并冠状动脉扩张和急性肾损伤(AKI)并不常见。

病例介绍

我们报告了一名17个月大的男童,其携带一种新的XIAP变异体。根据HLH-2004诊断标准,他最初被诊断为EBV-HLH,且该病症伴有冠状动脉扩张和急性肾损伤。对外周血来源的DNA进行综合基因分析发现XIAP基因存在半合子变异[c.116G>C(p.G39A)],该变异体遗传自他的母亲(杂合状态)。除支持治疗外,联合使用利妥昔单抗、静脉注射免疫球蛋白、糖皮质激素、抗病毒药物和霉酚酸酯(MMF)进行治疗后,他的临床表现和实验室指标有所改善。在8个月的随访中,患者通过MMF治疗实现了完全缓解。

结论

我们首次在一例与EBV-HLH相关的XLP-2病例中报告了XIAP基因中的[c.116G>C(p.G39A)]变异体。对于患有严重EBV-HLH的男性患者,应考虑XLP的可能性,并尽早进行分子遗传学检测以辅助诊断。儿童EBV-HLH合并冠状动脉扩张和AKI的报道罕见。对于EBV-HLH患者,应定期监测彩色多普勒超声心动图和尿液检查。必要时,可进行肾活检以明确病理。利妥昔单抗、免疫抑制剂和支持治疗取得了良好效果,但需要长期随访。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e4b/7531141/0c27c31b0b19/12887_2020_2359_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验